Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer
Open Access
- 8 November 2018
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Oncology
- Vol. 4 (11) , e181564
Abstract
The Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALTTO) trial demonstrated that trastuzumab, a monoclonal antibody against HER2, and lapatinib, a small-molecule tyrosine kinase inhibitor of the EGFR and HER2 family, administered together with paclitaxel chemotherapy in the neoadjuvant setting increased rates of pathologic complete response (pCR) by approximately 20% in patients with early-stage HER2-positive breast cancer compared with either treatment alone.1 A higher tumor-associated lymphocyte count2 and a higher expression of immune signatures3 were associated with higher rates of pCR but not with specific benefit from dual treatments. In this study, we examine whether specific T-cell receptor (TCR) species could indicate an association with response to a specific treatment arm.Keywords
This publication has 7 references indexed in Scilit:
- Assessment of T-cell receptor repertoire and clonal expansion in peripheral T-cell lymphoma using RNA-seq dataScientific Reports, 2017
- RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 TherapyJAMA Oncology, 2017
- Single-cell TCRseq: paired recovery of entire T-cell alpha and beta chain transcripts in T-cell receptors from single-cell RNAseqGenome Medicine, 2016
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and TrastuzumabJAMA Oncology, 2015
- CD4+ follicular helper T cell infiltration predicts breast cancer survivalJournal of Clinical Investigation, 2013
- Distinct Memory CD4+ T Cells with Commitment to T Follicular Helper- and T Helper 1-Cell Lineages Are Generated after Acute Viral InfectionImmunity, 2013
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialThe Lancet, 2012